Scalable B-B Single-Bond Formation via Boron-Centered Carboranyl Radicals: Boryl-Carborane for Boron Neutron Capture Therapy Applications.

Authors

Peng Zhou, Jiaxu Liu, Ruxia Hu, Jinzhong Wu, Chris Soon Heng Tan, Zuowei Xie

Published in

Journal of the American Chemical Society. Jul 14, 2026. Epub Jul 14, 2026.

Abstract

For many decades, interest in the medical application of boron chemistry focuses mainly on the boron neutron capture therapy (BNCT) approach to cancer treatment, which is a transformative binary-targeted radiotherapeutic modality, yet its global clinical translation is limited by the lack of high-performance boron delivery agents. Icosahedral carboranes hold unparalleled potential for the development of BNCT agents due to their exceptional boron density, excellent metabolic stability, and unique 3D architecture, but their biomedical application is hampered by intrinsic superhydrophobicity, poor tumor targeting, and limited theragnostic modifiability. Herein, we report a class of boryl-carboranes as multifunctional boron-bearing building blocks that directly address these long-standing limitations. The pendant borane moiety is readily converted to B(OH)₂ for tumor targeting and enhanced aqueous solubility, and to BF₃K for ¹⁸F-PET theragnostic integration. To enable scalable synthesis, we develop the electron donor-acceptor (EDA) complex-based strategy for the controllable generation of boron-centered carboranyl radicals from N-hydroxyphthalimide (NHPI) carboranyl carboxyl esters. This additive-free, room-temperature photochemical strategy enables boron-centered carboranyl radical-mediated unsymmetrical B-B bond construction, with decagram-scale production achieved via a continuous-flow system. Mechanistic studies confirm the EDA complex-mediated radical pathway. In vitro and in vivo studies demonstrate that these boryl-carboranes exhibit excellent biosafety, favorable aqueous solubility, and better tumor boron uptake and accumulation than clinically established agents, rendering this platform potential for next-generation BNCT therapeutics.

PMID:
42444541
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.